Medicine Supply Notification

Fluticasone 125microgram / Salmeterol 25microgram (Combisal®) pressurised metered dose inhaler (pMDI)
Tier 2 – medium impact*
Date of issue: 03/08/2022
Link: Medicines Supply Tool

Summary

- Fluticasone 125microgram / Salmeterol 25microgram (Combisal®) pressurised metered dose inhaler (pMDI) is out of stock until late-September 2022.
- Alternative brands of fluticasone 125microgram with salmeterol 25microgram inhalers (pMDI) remain available.
- A Serious Shortage Protocol (SSP) was issued on 22/07/2022.

Actions Required

For patients with insufficient supplies, community pharmacists may supply an alternative brand of fluticasone 125microgram with salmeterol 25microgram inhaler pMDI in accordance with the SSP for eligible patients.

If the patient is deemed ineligible or does not consent to receive an alternative product via the SSP, clinicians can consider prescribing:
- an alternative brand of fluticasone 125microgram with salmeterol 25microgram inhaler (pMDI) if this device is still deemed the most appropriate (see supporting information); or
- a suitable alternative medicine.

Ensure that the patient is not intolerant to any of the excipients and appropriate counselling and monitoring of asthma control is undertaken after switching inhaler treatment (see supporting information).

Supporting information

Clinical Information

Fluticasone 125microgram / Salmeterol 25microgram (Combisal®) inhaler is a pressurised inhalation suspension (pMDI), licensed for the treatment of asthma in patients from age 12 years upwards at a dose of 2 actuations twice a day. It is compatible with the AeroChamber Plus® spacer.

There are two alternative products currently available that cover a similar licensed age range (from 12 years upwards) to Fluticasone 125microgram / Salmeterol 25microgram (Combisal®) inhaler and are also dosed at 2 actuations twice a day.

*Classification of Tiers can be found at the following link: https://www.england.nhs.uk/publication/a-guide-to-managing-medicines-supply-and-shortages/
Fluticasone 125microgram / Salmeterol 25microgram (Aloflute®) pMDI and Fluticasone 125microgram / Salmeterol 25microgram (Sirdupla®) pMDI contain ethanol.

<table>
<thead>
<tr>
<th>Alternative inhalers</th>
<th>Compatible spacer</th>
<th>Availability</th>
<th>Licensed age group</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fluticasone 125microgram / Salmeterol 25microgram (Aloflute®) pMDI</td>
<td>AeroChamber Plus®</td>
<td>In stock and can support a full uplift</td>
<td>18+</td>
</tr>
<tr>
<td>Fluticasone 125microgram / Salmeterol 25microgram (Airflusal®) pMDI</td>
<td>Volumatic® or AeroChamber Plus®</td>
<td>In stock but cannot support an uplift</td>
<td>18+</td>
</tr>
<tr>
<td>Fluticasone 125microgram / Salmeterol 25microgram (Avenor®) pMDI</td>
<td>AeroChamber Plus®</td>
<td>In stock but cannot support an uplift in demand</td>
<td>12+</td>
</tr>
<tr>
<td>Fluticasone 125microgram / Salmeterol 25microgram (Sereflo®) pMDI</td>
<td>N/A*</td>
<td>In stock and can support a full uplift</td>
<td>18+</td>
</tr>
<tr>
<td>Fluticasone 125microgram / Salmeterol 25microgram (Seretide® 125 evohaler) pMDI</td>
<td>Volumatic®</td>
<td>In stock and can support a full uplift</td>
<td>12+</td>
</tr>
<tr>
<td>Fluticasone 125microgram / Salmeterol 25microgram (Sirdupla®) pMDI</td>
<td>AeroChamber Plus®</td>
<td>In stock and can support a full uplift</td>
<td>18+</td>
</tr>
</tbody>
</table>

*Manufacturer advises spacer devices are not compatible – if spacer device required switch to alternative fixed-dose combination preparation.

Asthma UK suggests a follow-up appointment with the GP or asthma nurse 6-8 weeks after starting a new inhaler; sooner if asthma control worsens after the switch.

Prescribers may also consider switching to an inhaler with a lower carbon footprint if deemed appropriate for the patient, in consultation with the patient/carer (see link below for further information).

Links to further information:

Please see the link for further information on the Fluticasone 125microgram / Salmeterol 25microgram (Combisal®) inhaler SSP.

SmPCs
Fluticasone 125microgram / Salmeterol 25microgram (Aloflute®) pMDI
Fluticasone 125microgram / Salmeterol 25microgram (Airflusal®) pMDI
Fluticasone 125microgram / Salmeterol 25microgram (Avenor®) pMDI
Fluticasone 125microgram / Salmeterol 25microgram (Sereflo®) pMDI
Fluticasone 125microgram / Salmeterol 25microgram (Seretide® 125 evohaler) pMDI
Fluticasone 125microgram / Salmeterol 25microgram (Sirdupla®) pMDI

Asthma resources
BNFC Chronic asthma summary
CKS: Asthma - Inhaled corticosteroids
Asthma UK: What to do when your medicine changes
How to reduce the carbon footprint of inhaler prescribing

Enquiries
If you have any queries, please contact DHSCmedicinesupplyteam@dhsc.gov.uk.